We’ve published this article as an earlier piece on UCITS catastrophe bond fund performance was incorrect, there was an error in the data we received. Based on new data, the average return of UCITS cat bond funds tracked by the Plenum CAT Bond UCITS Fund Indices was flat at the first pricing in May, but … Read more
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of … Read more
By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company … Read more
By M. Marin NASDAQ:GMGI READ THE FULL GMGI RESEARCH REPORT STRONG 2024 GROWTH; MOMENTUM EXPECTED TO CONTINUE IN 2025/BEYOND Revenue growth across all business lines Golden Matrix Group (NASDAQ:GMGI), an iGaming group providing a broad array of gaming products and software solutions on a B2B and B2C basis, reported 4Q24/2024 results this week, turning in … Read more
By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results On March 11, 2025, Sadot Group (NASDAQ:SDOT) reported 4th quarter and full year 2024 results which showed continued strength in the commodity trading business. In the latest filings, the restaurant operations have been reported as discontinued … Read more